Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Results Later Period Baseline Demographic and Clinical Characteristics SGLT2i Cohort After applying all inclusion and exclusion criteria, the new-user cohort included 94,080 patients with a mean age of 73.1 (SD 8.9) years, of whom 47.0% were female, 56.1% were white, 46.0% had obesity, and 26.0% were current smokers (Table 1)
SURMOUNT-1 for tirzepatide 15 mg)
The clinical evidence base is substantial, and understanding it helps you contextualize what to reasonably expect - while keeping in mind that trial results reflect brand-name medications in controlled settings, not real-world outcomes from any specific compounded program
Ku80-targeted pH-sensitive peptide-PNA conjugates are tumor selective and sensitize cancer cells to ionizing radiation
US$ 25.46
US$ 24.01
US$ 23.33
